A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
Obesity hypoventilation syndrome and metabolic failure at end of life — the mechanisms, the population, and the clinical reality of a diagnosis that medicine has too often misnamed, mismanaged, and stigmatized.
Obesity hypoventilation syndrome (OHS) is defined by three criteria: BMI above 30 kg/m², daytime hypercapnia (PaCO₂ >45 mmHg) on arterial blood gas, and the exclusion of other explanatory causes of hypoventilation. It produces chronic hypercapnic respiratory failure through mechanisms that are entirely distinct from obstructive lung disease. The excess adipose tissue of severe truncal obesity physically compresses the thoracic cage and diaphragm, reducing functional residual capacity (FRC) — sometimes by 50% or more from normal — and forcing the respiratory muscles to work against a chronically elevated mechanical impedance. This effect is dramatically worsened in the supine position, where abdominal visceral fat exerts direct upward pressure on the diaphragm, explaining why supine positioning is not a comfort preference issue in OHS — it is a clinical emergency in disguise. Simultaneously, the severe leptin resistance of morbid obesity impairs the central hypothalamic regulation of respiratory drive, blunting the normal physiological response to rising CO₂. The patient's brain has been chemically trained to tolerate hypercapnia as its new baseline. The combination of mechanical obstruction and impaired central drive produces a respiratory failure that PAP therapy — specifically BiPAP, not CPAP — must actively override by providing pressure support during inspiration.[2]
The patient who arrives at hospice enrollment with OHS has typically traversed a decade-long trajectory of escalating comorbidities managed by multiple specialists who treated each system independently. The sleep physician prescribed CPAP for OSA (often undertreated because CPAP alone is inadequate for OHS with daytime hypercapnia). The cardiologist managed the HFpEF with diuretics without integrating the pulmonary hypertension driven by nocturnal hypoxemia. The endocrinologist titrated insulin while the A1c remained poorly controlled in the setting of progressive autonomic neuropathy. The mobility declined from independent ambulation to walker to wheelchair to hospital bed in the living room — often over two to three years that the family navigated with inadequate equipment and no clinical coordination. By hospice enrollment, the patient has often not been fully out of bed in months. Every care interaction requires two people and specialized bariatric equipment. The caregiver has been sustaining a physically and emotionally exhausting care burden that the medical system has provided minimal support for.[5]
The metabolic failure cluster that accompanies OHS at end of life is not a collection of separate diagnoses — it is a single dysfunctional adipose tissue endocrine syndrome expressing itself simultaneously across organ systems. Dysfunctional adipose tissue secretes an altered adipokine profile — reduced adiponectin, leptin resistance, elevated TNF-alpha and IL-6 — driving systemic inflammation, insulin resistance, endothelial dysfunction, hepatic lipid accumulation (MASH/NASH), and renal hyperfiltration that eventually transitions to diabetic nephropathy. When three or more of these end-organ expressions reach advanced or end-stage simultaneously, the prognosis converges on that of advanced malignancy. The hospice clinician managing OHS and metabolic failure is managing a complex, multi-system terminal disease — not a lifestyle consequence.[3]
Before you assess vital signs, before you auscultate the chest, before you ask about pain — look at the head-of-bed angle. The OHS patient who has been repositioned flat by a well-meaning aide during wound care, or who drifted flat while sleeping, has been slowly accumulating CO₂ since the last position change. The head of bed must be elevated a minimum of 30 degrees at all times — 45 degrees is the clinical target. The prohibition on supine flat positioning is a clinical order, not a care preference, and it must be documented, posted in the room, and communicated to every caregiver before the first visit ends. Positioning in OHS is as therapeutically important as the BiPAP and far more immediately impactful than any medication adjustment.
OHS diagnostic criteria and the clinical data the hospice clinician must understand from prior records. Most patients arrive with an established diagnosis — this section helps you read it accurately and identify what the prior workup may have missed.
Your person has a condition where their body's weight makes it very hard to breathe normally, especially during sleep and when lying flat. Over time, the body gets used to having too much carbon dioxide — the waste gas from breathing — in the blood. This affects how alert and rested they feel, how their heart and lungs work, and how much energy they have. The machine they use to help them breathe at night (the BiPAP or CPAP) is one of the most important tools keeping them comfortable. The care team will be checking their breathing carefully at every visit — including making sure the head of the bed is at the right angle, because the position of the bed directly affects how well they can breathe.
The pathogenesis of OHS and the metabolic failure cluster — including the neuroendocrine disease model that reframes obesity from a lifestyle consequence to a complex biological syndrome with specific, mechanistically understood pathology.
This is one of the most important questions you may be carrying, and it deserves a direct answer. Your person's weight is a medical condition with complex biological, genetic, and environmental roots — not a personal failure or a result of poor choices. The science is clear: severe obesity involves genetic susceptibility to weight gain, hormonal dysregulation that makes weight loss extremely difficult to sustain, and the effects of food environments, stress, sleep deprivation, and medications that drive weight up over years. The medical system has spent decades treating obesity as a character flaw and has done enormous harm. What your person has been living with — the breathlessness, the restricted mobility, the complex medical care — is the result of a real disease. The hospice team is here to treat that disease with clinical seriousness and without judgment about how we got here.
At the first hospice visit, say this directly and without qualification: "I want to name something important — your weight is a medical condition with real and complex biological causes, and the care we provide is not conditional on any weight management goal or any prior choices. We are not going to be discussing weight loss. We are going to be managing your breathing and your comfort with the same precision we would bring to any other serious illness." Watch what happens in the room when you say this. The patient who has spent decades in clinical settings where their weight was the implicit or explicit explanation for every symptom — who has been told to "try harder," who has been denied procedures and referrals, who has internalized the medical system's stigma as a self-assessment — receives this statement as one of the most therapeutically significant things any clinician has said to them. It resets the clinical relationship before the first assessment begins.
PAP therapy decisions and settings, BiPAP at hospice enrollment, opioid initiation in the CO₂-retaining patient, diuresis, glucose management, bariatric surgical history, and the specific considerations of managing the metabolic failure cluster simultaneously.
PAP therapy is the foundational respiratory management in OHS and the clinical decision at the center of every hospice enrollment conversation for this diagnosis. Understanding the distinction between device types, the physiological rationale for higher settings in OHS, and the framework for continuing versus withdrawing BiPAP at hospice enrollment is essential clinical knowledge for every member of the hospice team managing this patient. The BiPAP that has been managing hypercapnia is providing genuine physiological comfort — it is reducing the CO₂ that causes morning headache, mental fog, air hunger, and daytime somnolence. Continuing it is consistent with comfort-focused care. Withdrawing it requires the same explicit goals-of-care conversation and planned comfort medication protocol as withdrawing ventilator support.[15]
Evidence-based criteria for continuing and initiating the specific interventions that provide genuine comfort benefit in OHS hospice. These are not disease-directed therapies — they are comfort-directed clinical protocols.
In OHS hospice, the most impactful interventions are not medications — they are protocols. The positioning protocol and the skin integrity protocol are the two highest-yield clinical interventions at enrollment, both preventing acute clinical crises (respiratory decompensation, severe pressure injury) that would otherwise dominate the clinical picture and impair quality of life. Establish these as clinical orders with the same formality as medication prescriptions. Every item on this list should be addressed at the first hospice visit.[12]
Specific interventions, routines, and clinical habits that cause harm in OHS hospice. Many are well-intentioned standard-of-care practices that must be explicitly prohibited in this diagnosis.
OHS is a diagnosis where standard clinical practices — designed for patients without the specific physiological vulnerabilities of severe obesity — can cause acute harm. The prohibition on supine positioning is the most important single clinical rule in this disease. Every other item on this list flows from the same principle: generic hospice care protocols must be explicitly modified for OHS-specific physiology at every point of care.[12]
The most common preventable clinical crisis in OHS hospice is not a medication error — it is a positioning failure. An aide who positions the patient flat for morning care, who then leaves without restoring head-of-bed elevation, has initiated a process of CO₂ accumulation that may produce acute confusion, somnolence, and apparent clinical deterioration within 30–60 minutes. The family who calls reporting "sudden confusion" or "they won't wake up" after a morning care visit has described a positioning-related hypercapnic event until proven otherwise. The immediate intervention is: restore head-of-bed elevation to 45 degrees, apply BiPAP if available and tolerable, call the nurse. This is not a 911 situation in a comfort-focused plan of care — but it requires an NP or RN response, opioids and anxiolytics available, and an explicit positioning re-education at the next aide supervisory visit.
Evidence-graded non-pharmacological and integrative approaches specific to OHS and metabolic failure at end of life. Grade A = RCT or strong physiological evidence; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical or expert consensus; D = expert opinion/case series.
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to OHS and metabolic failure. The weight-loss supplement predatory marketing landscape and the CNS-depressant supplement safety issue both require direct clinical engagement.
Obesity hypoventilation syndrome and metabolic failure create a supplement safety landscape dominated by three simultaneous concerns: (1) CO₂ retention makes any CNS-depressant supplement potentially dangerous — even supplements with modest sedating properties can further suppress the already impaired respiratory drive in a patient with limited respiratory reserve. This is not a theoretical risk — it is a physiological reality. Evaluate every supplement with sedating properties for CNS-depressant additive effects before recommending it. (2) The metabolic comorbidity cluster creates simultaneous drug interaction complexity — the OHS patient is typically on furosemide, insulin or hypoglycemics, an ACE inhibitor or ARB, potentially warfarin or a DOAC, and multiple other medications. Supplement interactions must be evaluated against the full medication list, not in isolation. (3) Predatory weight-loss supplement marketing — the patient with severe OHS at end of life has almost certainly encountered dozens of weight-loss supplement advertisements and may be using supplements purchased independently. Ask directly: "Are you taking any supplements, vitamins, herbs, or anything purchased at a health food store or online? I want to know — not to judge, but because some of these interact with your medications." Weight-loss supplements have no role in OHS hospice care — name this directly and compassionately.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Melatonin | Grade C | 3–5 mg PO at bedtime (do not exceed 5 mg in OHS with CO₂ retention) | Sleep disruption from nocturnal hypoxemia and hypercapnia, positional discomfort; may reduce the anxiety component of nocturnal dyspnea and improve sleep architecture. Multiple small trials in COPD and palliative populations show modest benefit on sleep quality without harm at standard doses when BiPAP is in use nocturnally.[28] | OHS caution: At standard doses (3–5 mg), produces only mild sedation and is safe when BiPAP is in use nocturnally. Do not use high-dose melatonin (>5 mg) — excessive sedation risk in hypercapnic patients. No significant drug interaction with furosemide or standard diabetes medications. Minor CYP1A2 interaction — watch if on fluvoxamine. Do not use with warfarin (theoretical anticoagulant potentiation). |
| Magnesium | Grade C | Magnesium glycinate or citrate 200–400 mg PO at bedtime; or magnesium oxide 400 mg daily for constipation | Constipation (near-universal in OHS on opioids and with reduced mobility); muscle cramps from diuretic-induced hypomagnesemia (furosemide depletes magnesium significantly); sleep quality; leg cramps. Magnesium deficiency is extremely common in patients on loop diuretics — supplementation is often clinically appropriate as a medical correction rather than a purely herbal intervention.[29] | Drug interactions: Magnesium binds and reduces absorption of several medications if taken simultaneously — separate from levothyroxine by 4 hours, from antibiotics (fluoroquinolones, tetracyclines) by 2 hours. Renal dosing critical: Reduce dose or avoid if eGFR below 30 mL/min — magnesium accumulation in renal failure can produce hypermagnesemia with dangerous neuromuscular and cardiac effects. Check serum magnesium and renal function before initiating. Diarrhea with magnesium oxide at higher doses. |
| Ginger | Grade C | Ginger tea (fresh ginger root 1–2 g steeped); ginger capsules 250 mg BID-TID; ginger candies or lozenges PRN | Nausea — a dominant symptom in OHS from gastroparesis, autonomic neuropathy, GLP-1 agonist effects (if still on), and the CO₂-related nausea of hypercapnia. Multiple RCTs demonstrate ginger's superiority to placebo for nausea in chemotherapy and post-surgical settings; extrapolated to palliative nausea management. No respiratory concerns. Well-tolerated in the OHS population.[30] | Anticoagulant interaction: Ginger at culinary doses (tea, small amounts in food) is safe. Medicinal doses (>4 g/day) may modestly potentiate antiplatelet effects — use caution if on warfarin or DOAC and monitor INR if applicable. No significant interaction with furosemide, insulin, or metformin. Safe in renal impairment at recommended doses. |
| Turmeric / Curcumin | Grade C | Turmeric tea or dietary use; curcumin supplements 500 mg BID with black pepper extract (piperine) for bioavailability | Systemic inflammation — the adipose-tissue–driven inflammatory state of OHS (elevated TNF-alpha, IL-6) is the same biological target of curcumin's documented anti-inflammatory effects in preclinical and small clinical studies. Also used for joint pain (nearly universal in OHS from weight-bearing arthritis), and for the inflammatory component of MASH liver disease. Limited clinical evidence in OHS specifically, but strong preclinical anti-inflammatory signal and a reasonable safety profile.[31] | CYP3A4 interaction: Piperine (black pepper extract added for bioavailability) significantly inhibits CYP3A4 — potential to increase levels of many co-administered drugs including some statins, antifungals, and calcium channel blockers. Check the patient's full medication list. Anticoagulant interaction: Curcumin has antiplatelet properties — use caution with warfarin or DOACs. May lower blood glucose modestly — monitor if on insulin. Loose stools at high doses. |
| Probiotics | Grade C | Lactobacillus acidophilus / Bifidobacterium combination; 10–50 billion CFU daily with food; refrigerated preparation preferred | Gut dysbiosis from antibiotic use (candidal skin infections often treated with fluconazole, which alters gut flora); constipation from opioids and reduced mobility; nausea. The OHS patient on furosemide, antibiotics for skin infections, and opioids has high gut dysbiosis risk. Emerging evidence suggests gut microbiome disruption exacerbates systemic inflammation in obesity — probiotics may provide modest anti-inflammatory benefit as well.[32] | Immunocompromise caution: Do not use live-culture probiotics in patients on systemic corticosteroids at immunosuppressive doses, or in patients with ESRD on immunosuppression — risk of bacteremia or fungemia from translocation. The OHS patient receiving standard comfort-directed care without immunosuppression is at low risk. Separate from antibiotics by 2 hours. Generally safe with diuretics, insulin, and standard OHS medications. |
A guide, not a prediction. OHS and metabolic failure follow an episodic trajectory punctuated by acute decompensations — each one compressing the reserve faster than the last.
The OHS and metabolic failure trajectory differs fundamentally from malignancy. There is no single inflection point — instead, the patient accumulates systemic failures over years, with each acute decompensation leaving less reserve than before. The timeline is punctuated by respiratory infections that trigger acute hypercapnic crises, by BiPAP non-compliance events that produce dangerous CO2 accumulation, and by the progressive skin and mobility failures of severe immobility. What looks like a stable plateau is often a staircase decline — and what appears to be a modest exacerbation can produce rapid, severe deterioration in a patient with BMI above 50 and three or more simultaneous organ system failures.[1]
OHS medication management requires addressing the metabolic comorbidity cluster simultaneously. The medication list at enrollment is long. The systematic review applies the comfort-benefit question to every drug.
The OHS patient at hospice enrollment typically carries 8–15 medications from multiple specialists, none of whom has reviewed the list through a comfort-benefit lens. The systematic medication review at enrollment must apply one question to every drug: does this provide documented comfort benefit given the prognosis? Simultaneously, four clinical priorities must be established before leaving the first visit: (1) positioning and skin care protocols as clinical orders, not care preferences; (2) BiPAP continuation or optimization before any withdrawal decision; (3) opioid for dyspnea at appropriately low starting doses given CO2 retention; (4) glucose management simplified from a tight-control to a hypoglycemia-avoidance framework. Obesity pharmacokinetics: volume of distribution for lipophilic drugs is dramatically increased in severe obesity — lipophilic opioids (fentanyl) distribute widely; as metabolic failure advances and renal function declines, dosing must be reassessed. The GFR estimated by standard Cockcroft-Gault formula may be unreliable in severe obesity — clinical assessment of renal function trends is essential.[40]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Furosemide | Loop diuretic / HFpEF volume overload, lower extremity edema, dyspnea from pulmonary edema | 40–120 mg PO daily or BID | Cornerstone of volume management in obesity-related HFpEF. Higher doses often required in severe obesity — reduced oral bioavailability (40–70% in normal adults, potentially lower in severe gut edema) and elevated renal clearance from glomerular hyperfiltration. Titrate against edema burden, respiratory dyspnea, and daily weight. Target: comfort relief of edema and dyspnea, not dry weight. ⚠ As eGFR falls from diabetic nephropathy, furosemide efficacy decreases — may require IV or SQ route for adequate diuresis.[24] |
| Morphine | Opioid / Dyspnea — first-line for OHS-related air hunger and hypercapnic respiratory distress | 1–2.5 mg PO/SQ q4h ATC + 1–1.5 mg PRN q1h |
CO2 retention dosing — start lower than standard: OHS patients with chronic hypercapnia have impaired respiratory drive compensation; opioids can further suppress hypercapnic ventilatory response. Start at 1–2.5 mg PO q4h (not the standard 2.5–5 mg) and titrate by 25% increments every 48–72h. The goal is relief of dyspnea sensation, not sedation. Titrate against air hunger, not SpO2. ⚠ If eGFR below 30, switch to fentanyl — morphine-6-glucuronide accumulates in renal failure.[41] Evidence: low-dose systemic opioids reduce dyspnea without producing clinically significant hypercapnia in stable OHS at recommended doses. |
| Fentanyl | Opioid / Dyspnea and pain — renal failure alternative to morphine | 12.5–25 mcg SQ q4h ATC + 12.5 mcg PRN q1h (patch: 12–25 mcg/h) |
Preferred opioid when eGFR below 30 or dialysis-withdrawal scenario (Card #47). Fentanyl has no active renally-cleared metabolites. Highly lipophilic — volume of distribution dramatically increased in severe obesity; patch pharmacokinetics are unpredictable in severe obesity (subcutaneous fat thickness affects absorption). SQ fentanyl provides more predictable dosing than transdermal in severe obesity. ⚠ Highly lipophilic — larger loading dose may be needed; longer to steady state; longer clearance after discontinuation in severe obesity.[40] |
| Miconazole powder | Topical antifungal / Candidal intertrigo in skin folds | Apply to affected skin folds BID after skin fold hygiene |
First-line for candidal intertrigo in the panniculus, inframammary folds, groin, axillae, and any moist skin fold. Apply after gently cleaning and drying the fold — moisture perpetuates infection. Apply a thin layer, not thick coating. Continue for 2 weeks after resolution to prevent recurrence. Powder formulation preferred over cream in actively wet folds — cream can macerate further. Miconazole 2% powder is preferred over nystatin powder in most adults — superior efficacy against mixed dermatophyte-candidal infections.[33] |
| Zinc oxide ointment | Skin barrier / Moisture-associated skin damage (MASD), incontinence-associated dermatitis | Apply to at-risk skin folds and perineal area at every pad change |
Provides physical barrier against moisture, urine, and fecal material in MASD-prone areas. Apply as thin protective layer — not thick occlusive coating. Essential in the perianal and perineal region where incontinence is common in bedbound OHS patients. In areas with active candidal infection, use miconazole powder first, then barrier cream on surrounding uninfected skin. Combination regimen: miconazole for infection, zinc oxide for barrier protection, repositioning to reduce moisture accumulation.[31] |
| Nystatin powder | Topical antifungal / Alternative for miconazole-intolerant patients or oral candidiasis | 100,000 units/g powder — apply to folds BID; or swish/swallow 100,000 units/mL suspension QID |
Second-line to miconazole for skin folds — some patients prefer powder texture. Primary agent for oral candidiasis (common in BiPAP users — mask seal disrupts oral flora; mouth breathing increases candidal colonization). For oral candidiasis: swish 5 mL QID for 14 days. Oral candidiasis is common in OHS/BiPAP users — assess oral cavity at every visit, especially if patient reports mouth soreness or taste change.[33] |
| Melatonin | Chronobiotic / Nocturnal sleep disruption, sleep-wake cycle dysregulation from OHS/OSA | 3–5 mg PO 30 min before bedtime | Sleep in OHS is profoundly disrupted — nocturnal hypoxemia and hypercapnia from OSA/OHS produce fragmented architecture, frequent arousals, and daytime somnolence that compounds functional impairment. Melatonin provides mild chronobiotic effect and is safe with the metabolic comorbidity cluster. No significant drug interactions with furosemide, opioids, or diabetes medications. Standard doses produce only mild sedation — safe when BiPAP is in nocturnal use. ⚠ Avoid doses above 10 mg — excessive sedation in hypercapnic patients. Do not substitute for adequate BiPAP use at night.[57] |
| Basal insulin (glargine or detemir) | Insulin / Type 2 diabetes glycemic management — comfort-focused glucose target | Continue current basal dose; reduce by 20–40% if intake declining; target BG 140–250 mg/dL |
Continue basal insulin in patients already on insulin — simplify all other glucose-lowering agents. The glucose management goal in OHS hospice is hypoglycemia avoidance, not A1c targets. Symptomatic hyperglycemia (polydipsia, delirium, candidal infections) warrants treatment; asymptomatic hyperglycemia in a patient with expected prognosis of weeks does not warrant aggressive management. Reduce basal dose by 20–40% as oral intake declines to prevent hypoglycemia. Eliminate sulfonylureas (hypoglycemia risk), GLP-1 agonists (nausea, unnecessary in comfort focus), DPP-4 inhibitors (minimal benefit, extra pill), and SGLT-2 inhibitors (genital infections in fold areas, dehydration) at enrollment.[42] |
| Metformin — DISCONTINUE | Biguanide / Type 2 diabetes — discontinue criteria in OHS hospice | STOP if eGFR below 30 STOP if oral intake declining STOP if comfort-focused care |
Discontinuation criteria: eGFR below 30 mL/min/1.73m² (lactic acidosis risk); declining oral intake (risk of hypoglycemia and GI intolerance without adequate caloric intake); hepatic impairment from MASH liver disease; or enrollment in comfort-focused hospice care where A1c reduction provides no meaningful benefit. ⚠ Lactic acidosis risk from metformin accumulation in renal impairment is a genuine patient safety concern — do not continue metformin if eGFR is declining toward or below 30.[42] |
| Lorazepam | Benzodiazepine / Anxiety, dyspnea with anxiety component, acute agitation | 0.5–1 mg PO/SQ q6–8h PRN | Adjunctive for anxiety component of dyspnea — clinical trial evidence for benzodiazepines as sole dyspnea agents is limited; they reduce the anxiety that amplifies dyspnea perception. Use as PRN for acute anxiety episodes. Scheduled use for chronic dyspnea anxiety: consider 0.5 mg q6h scheduled if frequent breakthrough needed. ⚠ Use with caution in CO2 retainers — benzodiazepines further suppress hypercapnic ventilatory drive; start at lowest effective dose; monitor respiratory rate and sedation level; do not use as substitute for opioid-based dyspnea management.[41] |
| Midazolam | Benzodiazepine / Terminal agitation, refractory dyspnea in final hours | 2.5–5 mg SQ PRN q1–2h; or 10–20 mg/24h CSCI for refractory terminal agitation |
Reserved for terminal agitation and refractory dyspnea in final days. Have drawn and labeled in the comfort kit before it is needed. Short-acting, titratable, water-soluble (good for SQ infusion). In OHS final hours, CO2 narcosis often provides natural sedation — midazolam may be needed less than expected compared to COPD or malignancy. Goals-of-care conversation required before initiating CSCI midazolam for terminal agitation — document clinical reasoning and family awareness. |
| Glycopyrrolate | Anticholinergic / Terminal secretions, salivary hypersecretion | 0.2 mg SQ q4h; or 0.6–1.2 mg/24h CSCI |
Preferred over hyoscine (scopolamine) in conscious patients — no CNS effects, no confusion risk. Reduces secretion volume without eliminating secretions entirely. For terminal secretions in OHS: repositioning is always first (side-lying reduces pooling); glycopyrrolate for pharmacological management. Family education: "Death rattle" sounds worse than it feels — patients in the final hours are not distressed by the secretion sounds that family members find alarming. |
| Dexamethasone | Corticosteroid / Inflammation, appetite stimulation, dyspnea from airway edema; bronchospasm in OHS exacerbation | 4–8 mg PO/SQ daily or BID; taper after 7–10 days |
Short-term use for appetite stimulation, dyspnea from bronchospasm or airway inflammation, nausea. Use with caution in OHS with diabetes — dexamethasone causes dramatic glucose elevation and may require temporary insulin dose escalation. Monitor glucose at 48–72h after initiating. Do not use long-term in OHS hospice — Cushingoid effects, skin fragility in already-compromised skin, immunosuppression worsening skin fold infections. ⚠ Glucose elevation in diabetes: start insulin correction scale if glucose above 300 mg/dL on dexamethasone.[42] |
| Spironolactone | Aldosterone antagonist / Diuresis augmentation, HFpEF management, refractory edema | 25–50 mg PO daily | Add-on to furosemide when edema is inadequately controlled by loop diuretic alone; particularly useful in obesity-related HFpEF where aldosterone excess contributes to fluid retention. Also has documented benefit in HFpEF independent of diuresis (TOPCAT trial data). ⚠ Hyperkalemia risk — check potassium before initiating and at 1–2 weeks; avoid if eGFR below 25 or potassium above 5.0 mEq/L; use caution with ACE inhibitors or ARBs.[25] |
| Gabapentin | Anticonvulsant / Neuropathic pain from diabetic peripheral neuropathy, restless legs, pruritus | 100–300 mg PO TID; renal dose-adjust if eGFR below 30 |
Diabetic peripheral neuropathy is nearly universal in the OHS metabolic failure cluster and produces pain, paresthesias, and sleep disruption that morphine alone does not adequately address. Gabapentin also addresses restless legs syndrome (very common in OHS with CKD) and uremic pruritus. ⚠ Gabapentin requires dose reduction in renal impairment: eGFR 30–60: max 1400 mg/day; eGFR 15–30: max 700 mg/day; eGFR below 15: max 300 mg/day. CNS sedation is additive with opioids — start low, monitor carefully for excessive sedation in CO2 retainers.[41] |
High-yield clinical pearls for the hospice team. OHS requires a different assessment protocol than any other hospice diagnosis — these are the things you learn after doing enough of these cases.
Dying from OHS carries a specific psychosocial burden unlike any other hospice diagnosis: the weight of decades of medical stigma, the grief of a body that has been judged throughout the entire disease course, and the exhaustion of caregivers who have been carrying a physically and emotionally demanding burden for years.
The patient dying from obesity hypoventilation syndrome and metabolic failure has navigated a medical system that treated their illness as a character flaw for their entire disease course. They have been told — by clinicians, by family members, by a culture saturated with weight stigma — that this was avoidable, that it is their fault, and that they could fix it if they tried harder. The OHS patient who arrives at hospice enrollment carries this accumulated burden alongside the physical symptoms of respiratory failure, skin breakdown, edema, and pain. The hospice team that does not explicitly address this burden will deliver incomplete care.[35]
The clinical obligation in OHS psychosocial care is not to provide the answers — it is to open the space for the patient's own experience to emerge without judgment, without redirection toward weight management, and without the implicit message that this death was preventable if they had made different choices. The chaplain who can sit with the rage, the grief, and the exhaustion of a patient who has navigated a stigmatizing medical system for decades — without rushing toward resolution or acceptance — provides irreplaceable and evidence-supported comfort.[36]
Research documents that patients with severe obesity report weight stigma in healthcare settings at rates above 70% — from primary care to specialist to emergency settings. The hospice encounter may be the first clinical interaction that approaches the patient without weight-focused judgment.[35]
The body of the severely obese patient has been the subject of medical commentary, public commentary, family commentary, and self-commentary throughout their life. At end of life, that same body now requires intimate and dignified care from clinicians and caregivers in the most vulnerable moments of life.[36]
Caregivers of severely obese patients at home have one of the highest rates of musculoskeletal injury and physical exhaustion of any caregiver population. The physical demands of bariatric home care — repositioning, transfers, wound care requiring fold lifting — exceed what standard caregiver support addresses.[47]
The caregiver of an OHS patient carries a grief that is different from the grief of other hospice caregivers — they have often been providing intensifying care for years before hospice enrollment, have watched a person they love lose mobility, independence, and quality of life incrementally, and may carry ambivalent feelings about the relationship being defined entirely by physical care demands.[48]
Spiritual care in OHS has a specific dimension beyond standard hospice spiritual assessment — the patient is dying from a disease that culture has framed as moral failure. The spiritual question in OHS is not only "what gives you meaning?" but also "have you been able to find peace with your body and your life, given everything you've been told?" The FICA framework (Faith/beliefs, Importance, Community, Address) provides the structural starting point; the OHS-specific addition is an explicit opening for the patient's experience of medical and social judgment.[37]
F — Faith/Beliefs: "What gives you strength during this time? Do you have spiritual beliefs that are important to you?" I — Importance: "How important is spirituality or faith in how you're coping?" C — Community: "Is there a faith community, spiritual leader, or group of people who should know you're ill and might want to support you?" A — Address + OHS Addition: "Is there anything you've been carrying — from the way your illness has been treated, or from things people have said about your weight — that you'd want to set down? Some people carry a lot of guilt about this illness that doesn't belong to them."
Depression affects 20–40% of patients with severe obesity and is substantially higher in the OHS hospice population. OHS-specific confounders: somnolence from CO2 retention mimics depression; functional limitation from immobility produces hopelessness with physiological rather than psychological origin; the chronic experience of stigma produces learned helplessness.[35]
Anxiety in OHS has a physiological component — the air hunger of hypercapnic respiratory failure is one of the most anxiety-provoking physical experiences in medicine — and a psychological component arising from the existential terror of drowning in a body that was never adequately treated. Treat both simultaneously.[7]
Plain language for families and caregivers. Share, print, or read aloud at the bedside. The positioning rule in this guide is a medical requirement — not a preference.
Your person's illness — obesity hypoventilation syndrome — affects the way the body breathes, particularly when lying down. The weight of body tissue around the chest makes the lungs work harder and makes it harder for the body to clear carbon dioxide, the waste gas from breathing. This produces breathlessness, drowsiness, and over time, a quieter and more gradual dying than many families expect. The most important thing you can do — right now, every day — is keep the head of the bed elevated. This is not a comfort preference. This is a medical requirement that keeps the carbon dioxide from building up and the breathing from getting worse. Everything else in this guide matters, but that matters first.[19]
Your person must NEVER be positioned flat on their back.
Minimum position: 30 degrees head elevation (about the same as a recliner at its lowest)
Preferred position: 45 degrees head elevation (about halfway to sitting)
This applies at all times — during sleep, during care, during rest.
After any repositioning to the side, always return the head to at least 30 degrees before leaving the room.
A recliner chair provides excellent positioning for patients who can safely transfer.
If someone positions your person flat on their back — call the nurse before the next visit.
Breathing suddenly much worse — not just the usual breathlessness, but a sudden significant change in breathing effort, breathing rate, or breathing comfort — regardless of position
Your person cannot get the BiPAP mask on and is in severe respiratory distress — administer any prescribed emergency medications, position at 45 degrees, call immediately
New severe confusion or unresponsiveness — a sudden change in mental status that is different from the drowsiness they normally have
Your person cannot be awakened or is very difficult to rouse
Skin breakdown — any area of open skin in a skin fold, on the heels, on the sacrum, or anywhere on the body
Blood sugar below 70 mg/dL with symptoms (sweating, confusion, shakiness) or below 50 mg/dL regardless of symptoms
Chest pain, sudden worsening of leg swelling, or signs of blood clot (one leg suddenly much more swollen than the other, or redness and warmth in one leg)
🙏 You have been providing care for your person in a situation that required remarkable physical and emotional strength — often for years before hospice was involved. The lifting, the repositioning, the skin care, the 2 AM adjustments, the equipment that fills the room — this is caregiving at a level of physical and emotional intensity that most people never experience. What you are doing matters, and it is seen. Please take care of yourself as you take care of them. Call us not just when your person needs something — call us when you need something too. Your wellbeing is part of our clinical responsibility.
Clinical field wisdom from 12+ years at the bedside with OHS and metabolic failure patients. Not guidelines. Real. Specific. The things you learn after doing enough of these cases.
Peer-reviewed citations organized by clinical category. Evidence levels assigned by article type. PMIDs hyperlinked to PubMed where available.
terminal2.care content is for educational purposes only and is not a substitute for clinical judgment. References represent peer-reviewed literature available at time of authorship. PMID links direct to PubMed abstracts; DOI links direct to publisher pages. Evidence level designations: RCT = randomized controlled trial; Meta = meta-analysis; Sys = systematic review; Obs = observational/cohort; Guide = clinical practice guideline; Review = narrative review; Expert = expert opinion/case series. Card #51 — Obesity Hypoventilation / Metabolic Failure — authored for Terminal2. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.